Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Immunology/Inflammation >> Complement System

Complement System

The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. The complement system consists of a number of small proteins found in the blood, in general synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex. Over 30 proteins and protein fragments make up the complement system. Three biochemical pathways activate the complement system: the classical complement pathway, the alternative complement pathway, and the lectin pathway.

Targets for  Complement System

Products for  Complement System

  1. Cat.No. Product Name Information
  2. GC38880 (Z)-Leukadherin-1

    ADH-503 free base

     (Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses. (Z)-Leukadherin-1 Chemical Structure
  3. GC60040 ADH-503

    (Z)-Leukadherin-1 choline

     ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses. ADH-503 Chemical Structure
  4. GC69582 ARC186

    ARC 186 is a nucleic acid adapter that serves as an efficient complement inhibitor by blocking the activation of C5 catalyzed by convertase.

     ARC186 Chemical Structure
  5. GC73413 ARC186 sodium ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to 0 Avacincaptad pegol (ARC1905) sodium. ARC186 sodium Chemical Structure
  6. GC70987 Avacincaptad pegol sodium Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol sodium Chemical Structure
  7. GC72391 Avdoralimab Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab Chemical Structure
  8. GC35481 BCX 1470 BCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin. BCX 1470 Chemical Structure
  9. GC35482 BCX 1470 methanesulfonate BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin. BCX 1470 methanesulfonate Chemical Structure
  10. GC35575 C3a (70-77) TFA

    Complement 3a (70-77) (TFA)

     C3a (70-77) TFA Chemical Structure
  11. GC31928 C3a 70-77 (Complement 3a (70-77)) C3a 70-77 (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a. C3a 70-77 (Complement 3a (70-77)) Chemical Structure
  12. GC66410 Cemdisiran

    ALN-CC5

     Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. Cemdisiran Chemical Structure
  13. GC73106 Cemdisiran sodium

    ALN-CC5 sodium

     Cemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. Cemdisiran sodium Chemical Structure
  14. GC35724 Complement C5-IN-1 Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5). Complement C5-IN-1 Chemical Structure
  15. GC62901 Complement factor D-IN-2 Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 Chemical Structure
  16. GC15251 Compstatin Complement inhibitor Compstatin Chemical Structure
  17. GC17510 Compstatin control peptide control peptide for Compstatin, a complement inhibitor Compstatin control peptide Chemical Structure
  18. GC61469 Compstatin TFA Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA Chemical Structure
  19. GC67721 CP-447697 CP-447697 Chemical Structure
  20. GC72473 Crovalimab Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab Chemical Structure
  21. GC38162 Danicopan

    ACH-4471

     Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan Chemical Structure
  22. GC40775 Dexamethasone

    MK-125, NSC 34521

    Dexamethasone, as one member of the glucocorticoid family, can protect against arthritis-related changes in cartilage structure and function, including matrix loss, inflammation and cartilage viability.

     Dexamethasone Chemical Structure
  23. GC64796 Eculizumab

    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5.

     Eculizumab Chemical Structure
  24. GC60149 EG01377 dihydrochloride EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects. EG01377 dihydrochloride Chemical Structure
  25. GC64892 Factor B-IN-1 Factor B-IN-1 is a Factor B inhibitor extracted from patent WO2013164802A1, Example 24. Factor B-IN-1 Chemical Structure
  26. GC64878 Factor D inhibitor 6 Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC50 of 30 nM and a Kd of 6 nM. Factor D inhibitor 6 Chemical Structure
  27. GC36035 FD-IN-1 FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. FD-IN-1 Chemical Structure
  28. GC74552 Gefurulimab

    ALXN-1720

     Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation. Gefurulimab Chemical Structure
  29. GC62479 Iptacopan hydrochloride

    LNP023 hydrochloride

     LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. Iptacopan hydrochloride Chemical Structure
  30. GC68029 JPE-1375 JPE-1375 Chemical Structure
  31. GC62273 JR14a JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a Chemical Structure
  32. GC72354 Lampalizumab Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab Chemical Structure
  33. GC17263 Leukadherin 1 CD11b/CD18 activator Leukadherin 1 Chemical Structure
  34. GC36472 LNP023

    LNP023

     LNP023 (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. LNP023 Chemical Structure
  35. GC66874 N-((Allyloxy)carbonyl)-N-methyl-L-alanine N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease. N-((Allyloxy)carbonyl)-N-methyl-L-alanine Chemical Structure
  36. GC12342 NDT 9513727 C5a receptor (C5aR) competitive antagonist NDT 9513727 Chemical Structure
  37. GC71259 NH2-C6-ARC186 sodium NH2-C6-ARC186 sodium is a modified ARC186 with NH2-C6 that can be coupled to other peptides or molecules. NH2-C6-ARC186 sodium Chemical Structure
  38. GC69592 NRP1 antagonist 1

    NRP1 antagonist 1 (compound 12a) is an effective NRP1 inhibitor with an IC50 of 19.1 μM. It has potential for use in cancer research.

     NRP1 antagonist 1 Chemical Structure
  39. GC74354 Pegcetacoplan acetate Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate Chemical Structure
  40. GC69684 Pelecopan

    BCX9930

    Pelecopan (BCX9930) is an effective and selective complement factor D inhibitor with oral activity. Its IC50 value is 14.3 nM. Pelecopan can target complement factor D to prevent intravascular and extravascular hemolysis in PNH, as well as other diseases mediated by alternative pathways.

     Pelecopan Chemical Structure
  41. GC10449 PMX 205 C5a receptor peptide antagonist PMX 205 Chemical Structure
  42. GC34434 PMX 205 Trifluoroacetate PMX 205 Trifluoroacetate is a potent complement C5a receptor (C5aR; CD88) antagonist. PMX 205 Trifluoroacetate Chemical Structure
  43. GC50176 PMX 53

    3D53

     Potent C5a receptor antagonist PMX 53 Chemical Structure
  44. GC50238 PMX 53c Negative control for PMX 53 PMX 53c Chemical Structure
  45. GC63151 POT-4

    AL-78898A

     POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 Chemical Structure
  46. GC74590 Pozelimab

    REGN3918

     Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab Chemical Structure
  47. GC69803 Ravulizumab

    ALXN1210

    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds specifically and with high affinity to human complement protein C5. Ravulizumab can be used in the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

     Ravulizumab Chemical Structure
  48. GC72326 Riliprubart Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart Chemical Structure
  49. GC11800 SB 290157 (trifluoroacetate salt) SB 290157 (trifluoroacetate salt) is a potent and selective C3a receptor antagonist with an IC50 of 200 nM. SB 290157 (trifluoroacetate salt) Chemical Structure
  50. GC66348 Sutimlimab Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. Sutimlimab Chemical Structure
  51. GC70017 Tesidolumab

    LFG316; Anti-Human C5 Recombinant Antibody

    Tesidolumab (LFG316) is a fully human IgG1/Λ monoclonal antibody against C5, with a molecular weight of 143 kDa (excluding glycosylation). Tesidolumab (LFG316) blocks the cleavage of C5, preventing the subsequent formation of membrane attack complex.

     Tesidolumab Chemical Structure
  52. GC61335 TLQP-21 TFA TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA Chemical Structure
  53. GC63858 Vemircopan

    ALXN2050; ACH 0145228; ACH-5228

     Vemircopan (ALXN2050) is an orally active complement factor D inhibitor. Vemircopan Chemical Structure
  54. GC70116 Vesencumab

    MNRP-1685A

    Vesencumab (MNRP-1685A) is an IG1 antibody targeting neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and blocks its coupling with VEGFR-2. Vesencumab has antiangiogenic and antitumor activity. Vesencumab can be used for research on metastatic solid tumors, including ovarian cancer.

     Vesencumab Chemical Structure
  55. GC17129 W 54011 C5a receptor antagonist W 54011 Chemical Structure
  56. GC70170 Zilucoplan

    RA101495

    Zilucoplan (RA101495) is a 15-amino acid cyclic peptide and an effective inhibitor of complement component 5 (C5). Zilucoplan can be used in research on immune-mediated necrotizing myopathy (IMNM).

     Zilucoplan Chemical Structure
  57. GC74045 Zoracopan Zoracopan is a selective complement factor D (CFD) inhibitor. Zoracopan Chemical Structure

56 Item(s)

per page

Set Descending Direction